Skip to main content

Table 4 Baseline characteristics of the MRA population by disease cohort

From: Patient characteristics and initiation of mineralocorticoid receptor antagonists in patients with chronic kidney disease in routine clinical practice in the US: a retrospective cohort study

Variable

MRA cohort

CKD

DKD

CKD + HF

DKD + HF

(n = 1574)

(n = 1574)

(n = 1004)

(n = 1747)

Age, years

 Mean (SD)

56.1 (13.0)

59.0 (10.6)

62.7 (13.5)

63.5 (10.7)

 Median

57.0

60.0

61.0

63.0

 Range

19 to 83

22 to 83

22 to 83

28 to 83

Men, n (%)

747

(47.5)

925

(58.8)

671

(66.8)

1113

(63.7)

Physician specialty, n (%)

 Primary care physician

207

(13.2)

166

(10.5)

106

(10.6)

173

(9.9)

 Internal medicine

258

(16.4)

280

(17.8)

163

(16.2)

310

(17.7)

 Cardiology

48

(3.0)

37

(2.4)

94

(9.4)

128

(7.3)

 Nephrology

602

(38.2)

666

(42.3)

210

(20.9)

430

(24.6)

 Hospital

176

(11.2)

152

(9.7)

190

(18.9)

295

(16.9)

 Other

241

(15.3)

235

(14.9)

211

(21.0)

370

(21.2)

 Unknown

42

(2.7)

38

(2.4)

30

(3.0)

41

(2.3)

Medications, n (%)

 Angiotensin II receptor blockers

539

(34.2)

704

(44.7)

258

(25.7)

573

(32.8)

 ACE inhibitors

609

(38.7)

817

(51.9)

460

(45.8)

924

(52.9)

 Renin inhibitors

46

(2.9)

55

(3.5)

13

(1.3)

50

(2.9)

 Β-blockers

735

(46.7)

993

(63.1)

710

(70.7)

1366

(78.2)

 Calcium-channel blockers

722

(45.9)

817

(51.9)

321

(32.0)

766

(43.8)

 Vasodilators

395

(25.1)

529

(33.6)

351

(35.0)

789

(45.2)

 Diuretics

778

(49.4)

953

(60.5)

694

(69.1)

1390

(79.6)

Comorbidities, n (%)

 Hypertension

1391

(88.4)

1516

(96.3)

949

(94.5)

1696

(97.1)

 CVD

275

(17.5)

412

(26.2)

641

(63.8)

1145

(65.5)

 IHD

245

(15.6)

388

(24.7)

595

(59.3)

1212

(69.4)

 LVH

106

(6.7)

156

(9.9)

390

(38.8)

668

(38.2)

 Anemia

518

(32.9)

576

(36.6)

436

(43.4)

941

(53.9)

 Hyperkalemia

95

(6.0)

109

(6.9)

75

(7.5)

216

(12.4)

Healthcare costs, $

 Mean

31,380

32,761

77,274

84,733

 95% CI

28,275 to 34,485

29,995 to 35,527

69,997 to 84,551

79,324 to 90,141

 SD

62,801

55,954

117,501

115,256

 Median

11,944

16,185

38,447

48,117

  1. ACE acetylcholinesterase, ARB angiotensin II receptor blocker, CKD chronic kidney disease, DKD diabetic kidney disease, HF heart failure, LVH left ventricular hypertrophy, m months, MRA mineralocorticoid receptor antagonist